17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.
Regulatory approvals and programme update
ReNeuron’s CTX cell line shows further potential
Newly published positive efficacy data in an accepted model of Huntington’s disease
07 May 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new positive data relating to its CTX cell therapy candidate have been published in the leading peer-reviewed scientific journal Stem Cells, in a paper entitled “Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington’s disease”.
Exosome Research Collaboration
07 April 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company’s proprietary exosomes to deliver novel therapeutics.
COVID-19 Update
03 April 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update in light of the COVID-19 pandemic and the effect on the Company of UK and US government measures to contain the spread of the disease.
Positive long-term data in retinal clinical trial
Meaningful clinical effect observed in patients out to 12 months post-treatment
Expansion of ongoing Phase 2a study includes plans to open a UK clinical site
24 February 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce positive long-term data from the ongoing Phase 1/2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP) and plans to expand the ongoing study. RP is a group of hereditary diseases of the eye that lead to progressive loss of sight and blindness.
Positive Phase 2a stroke clinical data published
17 February 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.
Interim Results for the six months ended 30 September 2019
6 December 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2019.
To log on to view a recording of the analyst presentation webcast please click here…
To view the Interim Results Presentation slide deck please click here…
UK BioIndustry Association’s (BIA) awards 2019
Sharon Grimster (ReNeuron) to be recognised at bioProcessUK conference
13 November 2019: Sharon Grimster of ReNeuron will be awarded the prestigious Peter Dunnill award at the UK BioIndustry Association’s (BIA) 16th bioProcessUK conference in Liverpool later this month.
To view the UK BioIndustry Association’s (BIA) press release please CLICK HERE.
ReNeuron’s lead cell line shows further potential
New data show ReNeuron’s lead CTX cell therapy candidate can be
re-programmed into a pluripotent state and differentiated into other cell types
These new cell types can be efficiently expanded as potential cell therapy candidates targeting a broad range of diseases
23 October 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Barcelona, Spain.
Positive clinical data presented at AAO meeting
Study investigator presents positive efficacy data in ongoing retinal disease clinical trial
14 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that positive efficacy data were presented during the weekend at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco from the Company’s Phase 1/2a clinical trial of its hRPC stem cell therapy in retinitis pigmentosa (RP).
To view the presentation please CLICK HERE.